These results go on to demonstrate that SRPK1 inhibition switches splicing of PD-1 to generate the antagonistic isoform, which enhances T cell killing of tumour cells, opening up the possibility of small molecule SRPK1 inhibitors as novel pharmacological immunotherapies. This evidence concerns the gene SRPK1 and neoplasm.